keyword
MENU ▼
Read by QxMD icon Read
search

U300

keyword
https://www.readbyqxmd.com/read/27710135/pharmacodynamic-and-pharmacokinetic-evaluation-of-insulin-glargine-u300-for-the-treatment-of-type-1-diabetes
#1
Kathryn M Hurren, Jessica L O'Neill
Glargine 300 units/ml (Gla-300) is a novel basal insulin formulation approved in 2015 for the treatment of diabetes. This more concentrated form of glargine causes delayed redissolution from the subcutaneous depot after injection and thus altered action profile. Areas covered: The pharmacokinetics, pharmacodynamics, efficacy, and safety of Gla-300 in patients with type 1 diabetes mellitus (T1DM) will be reviewed. Expert opinion: Gla-300 has a flatter and more prolonged pharmacokinetic profile compared to glargine 100 units/ml (Gla-100), but is less potent on a unit per unit basis...
December 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27593206/impact-of-the-mode-of-protraction-of-basal-insulin-therapies-on-their-pharmacokinetic-and-pharmacodynamic-properties-and-resulting-clinical-outcomes
#2
Tim Heise, Chantal Mathieu
Manufacturers of insulin products for diabetes therapy have long sought ways to modify the absorption rate of exogenously administered insulins in an effort to better reproduce the naturally occurring pharmacokinetics of endogenous insulin secretion. Several mechanisms of protraction have been used in pursuit of a basal insulin for which a low injection frequency would provide tolerable and reproducible glucose control; these mechanisms have met with varying degrees of success. Before the advent of recombinant DNA technology, development focused on modifications to the formulation that increased insulin self-association, such as supplementation with zinc or the development of pre-formed precipitates using protamine...
September 4, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27307429/basal-insulin-regime-change-from-lantus-to-toujeo-resulted-in-fewer-hypoglycaemic-episodes-in-a-28-year-old-man-with-diabetes-mellitus
#3
Alexandra Shields, Sailesh Sankaranarayanan
An active 28-year-old man with type 1 diabetes mellitus reported a reduced number of hypoglycaemic episodes following change in basal regime insulin glargine from U100 Lantus to U300 Toujeo. Consequently, an improved quality of life was also reported. Flash-based glucose monitoring was utilised to record 24-hour continuous glucose levels throughout two comparable 60-day periods before and after the change in regimen. Low blood glucose was most likely between 03:00 and 08:00. Nocturnal hypoglycaemic episodes (≤3...
2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27022271/concentrated-insulins-the-new-basal-insulins
#4
REVIEW
Elizabeth M Lamos, Lisa M Younk, Stephen N Davis
INTRODUCTION: Insulin therapy plays a critical role in the treatment of type 1 and type 2 diabetes mellitus. However, there is still a need to find basal insulins with 24-hour coverage and reduced risk of hypoglycemia. Additionally, with increasing obesity and insulin resistance, the ability to provide clinically necessary high doses of insulin at low volume is also needed. AREAS COVERED: This review highlights the published reports of the pharmacokinetic (PK) and glucodynamic properties of concentrated insulins: Humulin-R U500, insulin degludec U200, and insulin glargine U300, describes the clinical efficacy, risk of hypoglycemic, and metabolic changes observed, and finally, discusses observations about the complexity of introducing a new generation of concentrated insulins to the therapeutic market...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/26688145/the-new-long-acting-insulin-glargine%C3%A2-u300-achieves-an-early-steady-state-with-low-risk-of-accumulation
#5
L Monnier, D R Owens, G B Bolli
No abstract text is available yet for this article.
April 2016: Diabetes & Metabolism
https://www.readbyqxmd.com/read/26238470/new-insulin-glargine-300-u-ml-for-the-treatment-of-type-1-and-type-2-diabetes-mellitus
#6
REVIEW
Jennifer Goldman, John R White
OBJECTIVE: To describe the studies evaluating the efficacy and safety of new insulin glargine 300 U/mL (Gla-300) as a basal insulin in the treatment of type 1 (T1DM) and type 2 (T2DM) diabetes mellitus. DATA SOURCES: A literature search of MEDLINE was conducted (January 2008-June 2015) using the terms U300, Gla-300, and insulin glargine 300 units/mL and supplemented with congress abstracts published in 2014 and 2015. STUDY SELECTION AND DATA EXTRACTION: All English language studies assessing the efficacy and/or safety of Gla-300 were evaluated...
October 2015: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/25941658/basal-insulin-analogues-in-the-treatment-of-diabetes-mellitus-what-progress-have-we-made
#7
Sanjay Kalra
Over the past few decades, continuous progress has been made in the development of insulin therapy. Basal insulins were developed around 60 years ago. However, existing basal insulins were found to have limitations. An ideal basal insulin should have the following properties viz. longer duration of action, a flat time-action profile, low day-to-day glycaemic variability, and the potential for flexible dosing. Basal insulins have advanced over the years, from lectin and neutral protamine Hagedorn to the currently available insulin degludec...
April 2015: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/25311556/u300-a-novel-long-acting-insulin-formulation
#8
REVIEW
Gemma Sutton, Joan Minguet, Carmen Ferrero, Peter Bramlage
INTRODUCTION: Insulin glargine (100 U/ml; U100) was the first long-acting basal insulin analog to be introduced into clinical practice and it remains the most widely used. Although U100 is an effective and safe treatment, research is ongoing to optimize the time-action profile. The focus of this review is insulin glargine [rDNA origin] injection 300 U/ml (U300), a novel formulation that contains a higher concentration of insulin than U100. AREAS COVERED: The clinical efficacy and safety of U300 in patients with type 1 and type 2 diabetes mellitus are discussed, with an emphasis on recently released data from the Phase III EDITION clinical trials...
December 2014: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/25200067/-new-insulin-types-in-type-1-diabetes-mellitus
#9
REVIEW
Jordi Mesa
Since its discovery almost a century ago, insulin remains the mainstay of treatment of patients with type 1 diabetes mellitus. Although progress in the synthesis of new formulations has been remarkable, the physiological profile of insulin is still different from that observed with preparations available nowadays. In the last decade, the introduction into clinical practice of insulin analogues has allowed significantly improvement in glycemic control and has facilitated the spread of basal/bolus patterns, the most physiological ones until now...
July 20, 2015: Medicina Clínica
https://www.readbyqxmd.com/read/24673155/the-development-of-new-basal-insulins-is-there-any-clinical-advantage-with-their-use-in-type-2-diabetes
#10
REVIEW
Maria Ida Maiorino, Michela Petrizzo, Annalisa Capuano, Dario Giugliano, Katherine Esposito
INTRODUCTION: The basal insulin products currently on market do not optimally mimic endogenous insulin secretion. These unmet clinical needs have fueled the development of new basal insulin analogues for improving their pharmacokinetics/pharmacodynamics profile. AREAS COVERED: We review the recent literature investigating the efficacy and safety of new basal insulin analogues in type 2 diabetes, as in the USA, insulin utilization accounted for 26% of treatment visits for these patients in 2012...
June 2014: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/24026961/basal-insulin-analogues-in-the-management-of-diabetes-mellitus-what-progress-have-we-made
#11
REVIEW
David R Owens, Glenn Matfin, Louis Monnier
Insulin remains the most effective and consistent means of controlling blood glucose levels in diabetes. Since 1946, neutral protamine Hagedorn (NPH) has been the predominant basal insulin in clinical use. However, absorption is variable due to the need for resuspension and the time-action profile (peak activity 4-6 h after subcutaneous administration) confers an increased propensity for between-meal and nocturnal hypoglycaemia. In the 1980s, recombinant DNA technology enabled modifications to the insulin molecule resulting in the soluble long-acting insulin analogues, glargine and detemir...
February 2014: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/10500151/an-important-base-triple-anchors-the-substrate-helix-recognition-surface-within-the-tetrahymena-ribozyme-active-site
#12
A A Szewczak, L Ortoleva-Donnelly, M V Zivarts, A K Oyelere, A V Kazantsev, S A Strobel
Key to understanding the structural biology of catalytic RNA is determining the underlying networks of interactions that stabilize RNA folding, substrate binding, and catalysis. Here we demonstrate the existence and functional importance of a Hoogsteen base triple (U300.A97-U277), which anchors the substrate helix recognition surface within the Tetrahymena group I ribozyme active site. Nucleotide analog interference suppression analysis of the interacting functional groups shows that the U300.A97-U277 triple forms part of a network of hydrogen bonds that connect the P3 helix, the J8/7 strand, and the P1 substrate helix...
September 28, 1999: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/4040889/virulence-of-staphylococcus-aureus-in-a-mouse-mastitis-model-studies-of-alpha-hemolysin-coagulase-and-protein-a-as-possible-virulence-determinants-with-protoplast-fusion-and-gene-cloning
#13
P Jonsson, M Lindberg, I Haraldsson, T Wadström
Mutants of a genetically well-characterized strain of Staphylococcus aureus [SA113(83A)] were isolated after mutagenization. Alpha-hemolysin- (hla), coagulase- (coa), and protein A- (spa) negative mutants were characterized by more than 90 biochemical tests for production of extracellular proteins and biochemical profile to exclude pleiotropy. Protoplast fusion was then used to isolate double-defective (hla and coa) recombinants and recombinants with regained properties, i.e., production of alpha-hemolysin and coagulase...
September 1985: Infection and Immunity
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"